まとめ
5人の患者がアルミトリン・ディメシラートを服用した後に,感覚外周神経症を発症した. 症状には,足の感覚喪失と足首の振動の減少が含まれており,これは,潜在的に体重減少と関連しているディスタルアキソノパシーを示唆しています.
科学分野:
- 神経学 神経学とは
- 毒理学 毒理学 毒理学
背景:
- アルミトリンジメシラート (Almitrine dimesylate) は,呼吸器の刺激に使用される薬である.
- 周辺神経病は,特定の薬剤の潜在的な副作用である.
研究 の 目的:
- アルミトリンジメシラートで治療された患者で,感覚周辺神経病変の発生を報告する.
- この神経病の臨床的および電気生理学的特徴を調査する.
主な方法:
- アルミトリンジメシラート (60〜100 mg/日) を投与した5人の患者の症例シリーズ.
- 臨床検査,脳脊髄液分析,電気生理学および組織学の研究が行われました.
主要な成果:
- 5人の患者全員に,足の感知喪失 (ストッキング分布) と足首の振動の喪失が進行した.
- 電気生理学的および組織学的発見は,遠端アクソナパシーと一致しました.
- 症状の発症は,アルミトリンジメシラート投与開始から2〜4ヶ月後に4人の患者で発生しました.
- 症状が現れる前にすべての患者で体重減少 (4-15kg) が顕著であった.
結論:
- アルミトリンジメシラートは,遠端アキソナパシーによって特徴づけられる感覚周辺神経症を引き起こす可能性があります.
- 体重減少は,以前に結合されたアルミトリンジメシラートを放出することによって,神経病の発達に役割を果たす可能性があります.
- アルミトリンジメシラートの神経毒性作用に関するさらなる調査が必要である.
関連する概念動画
Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...


